Related Experiment Video
Updated: Aug 6, 2026
12:45
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
Advances in devices for cardiac resynchronization in heart failure
Chu-Pak Lau1, Serge Barold, Hung-Fat Tse
1Cardiology Division, Department of Medicine, University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, ROC.
Summary
Cardiac resynchronization therapy (CRT) effectively treats heart failure in patients with wide QRS complexes. CRT improves outcomes, reduces hospitalizations, and offers survival benefits over medical therapy alone.
Area of Science:
- Cardiology
- Medical Devices
- Heart Failure Management
Background:
- Advanced heart failure presents significant mortality and morbidity challenges.
- A substantial percentage of patients exhibit QRS duration ≥120 ms, indicating potential dyssynchrony.
- Cardiac resynchronization therapy (CRT) offers a solution for correctable dyssynchrony.
Purpose of the Study:
- To review the efficacy and technical aspects of CRT in heart failure patients.
- To highlight advancements in CRT implantation and device features.
- To discuss the management of arrhythmias and the impact of CRT on clinical outcomes.
Main Methods:
- Review of technical advances in CRT implantation, including guide sheaths and lead placement.
- Analysis of device-specific CRT features for optimizing heart failure management.
- Examination of CRT's role in managing comorbid arrhythmias like atrial fibrillation and ventricular tachyarrhythmias.
Main Results:
- CRT, typically via biventricular pacing with left ventricular lead in the coronary sinus, shows high success rates (88-92%).
- Technical innovations facilitate easier and more effective CRT implantation.
- CRT is associated with a 30% reduction in heart failure hospitalizations.
- Preliminary data suggest a survival benefit for CRT combined with implantable cardioverter defibrillators.
Conclusions:
- CRT is a valuable therapeutic option for selected heart failure patients with QRS duration ≥120 ms.
- Technological advancements have improved CRT delivery and management.
- CRT offers significant benefits in reducing hospitalizations and improving survival in advanced heart failure.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...